On May 22, Livzon Pharmaceutical Group Inc (China) announced the acquisition of a 64.81% stake in Imexpharm Joint Stock Company (IMP), equivalent to nearly 100 million shares. The deal is valued at approximately 5.731 trillion VND, with an average price of 57,400 VND/share, which is 13% higher than the market price at the time of the transaction. SK Investment will receive over 4.216 trillion VND from this transaction. Livzon indicated that the purpose of this acquisition is to expand into foreign markets and support sustainable development strategies. SK Group initially purchased 25% of Imexpharm in 2020 and gradually increased the stake to 65%. Recently, SK also divested from its investments in Masan and Vingroup. Livzon Pharmaceutical, established in 1985, specializes in research, production, and trading of pharmaceuticals, with revenue of 11.812 billion RMB in 2024.
Leave a Reply